Q-omics provides the consensus-scored ARHGEF34P profile across patient tissues and cancer cell-line models. ARHGEF34P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGEF34P is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ARHGEF34P RNA expression shows 18,314 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ARHGEF34P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF34P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF34P survival associations across molecular data types. ARHGEF34P RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF34P RNA expression–survival associations across cancer types. High ARHGEF34P expression shows unfavorable associations in CESC, LGG, BLCA and COAD, but favorable associations in KIRC and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGEF34P RNA expression.
This table summarizes ARHGEF34P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGEF34P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF34P shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in BLCA, HNSC and LUSC. The THCA box plot shows higher ARHGEF34P RNA expression in normal versus tumor tissue (log2 FC = −1.065, t-test p < 0.001).
This table shows molecular features associated with ARHGEF34P in patient tissues and cancer cell lines. In patient samples, ARHGEF34P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF34P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
